AZOLID Drug Patent Profile
✉ Email this page to a colleague
When do Azolid patents expire, and when can generic versions of Azolid launch?
Azolid is a drug marketed by Sanofi Aventis Us and is included in two NDAs.
The generic ingredient in AZOLID is phenylbutazone. There is one drug master file entry for this compound. Additional details are available on the phenylbutazone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AZOLID?
- What are the global sales for AZOLID?
- What is Average Wholesale Price for AZOLID?
Summary for AZOLID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 98 |
| Patent Applications: | 4,691 |
| DailyMed Link: | AZOLID at DailyMed |
US Patents and Regulatory Information for AZOLID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | AZOLID | phenylbutazone | CAPSULE;ORAL | 087260-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sanofi Aventis Us | AZOLID | phenylbutazone | TABLET;ORAL | 087091-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
